Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference
April 08 2021 - 7:30AM
Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines
company creating a new class of non-viral gene therapy, announced
today that Geoff McDonough, M.D., president and chief executive
officer, will participate in a fireside chat at the 20th Annual
Needham Virtual Healthcare Conference on Thursday, April 15, at
3:00 p.m. ET.
A live webcast of the fireside chat will be available on the
investor section of the company’s website at
investors.generationbio.com. A replay will be available there for
30 days following the event.
About Generation Bio
Generation Bio is an innovative genetic medicines company
focused on creating a new class of non-viral gene therapy to
provide durable, redosable treatments for people living with rare
and prevalent diseases. The company’s non-viral platform
incorporates a proprietary, high-capacity DNA construct called
closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle
delivery system, or ctLNP; and an established, scalable capsid-free
manufacturing process. The platform is designed to enable
multi-year durability from a single dose of ceDNA and to allow
titration and redosing if needed. The ctLNP is engineered to
deliver large genetic payloads, including multiple genes, to
specific tissues to address a wide range of indications. The
company’s efficient, scalable manufacturing process supports
Generation Bio’s mission to extend the reach of gene therapy to
more people, living with more diseases, in more places around the
world.
For more information, please
visit www.generationbio.com.
Contact:
Investors Maren KillackeyGeneration
Biomkillackey@generationbio.com541-646-2420
Media Alicia WebbGeneration
Bioawebb@generationbio.com847-254-4275
Stephanie Simon Ten Bridge
Communicationsstephanie@tenbridgecommunications.com617-581-9333
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024